Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice

Nigel Irwin, Kerry Hunter, Peter Flatt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY) are secreted from the intestinal K- and L-cells, respectively, following a meal. Both peptides are believed to play a key role in glucose homeostasis and energy expenditure. This study investigated the effects of daily administration of the stable and specific GIP-R antagonist, (Pro)GIP (25 nmol/ kg) and the endogenous truncated form of PYY, PYY(3-36) (50 nmol/kg), in mice fed with a high fat diet. Daily i.p. injection of (Pro(3))GIP, PYY(3-36) or combined peptide administration over 24 days significantly (P <0.05-0.01) decreased body weight compared with saline-treated controls without change in food intake. Plasma glucose levels and glucose tolerance were significantly (P <0.05) lowered by (Pro(3))GIP treatment alone, and in combination with PYY(3-36). These changes were accompanied by a slight improvement of insulin sensitivity in all of the treatment groups. (Pro(3))GIP treatment significantly reduced plasma corticosterone (P <0.05), while combined administration with PYY(3-36) significantly lowered serum glucagon (P <0.05). No appreciable changes were observed in either circulating or glucose-stimulated insulin secretion in all treatment groups. (Pro(3))GIP-treated mice had significantly (P <0.01) lowered fasting glucose levels and an improved (P <0.05) glycemic response to feeding. These comparative data indicate that chemical ablation of GIP receptor action using (Pro(3))GIP provides an especially effective means of countering obesity and related abnormalities induced by consumption of high fat energy rich diet. (C) 2007 Elsevier Inc. All rights reserved.
LanguageEnglish
Pages2192-2198
JournalPeptides
Volume28
Issue number11
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Fats
Glucose
Gastric Inhibitory Polypeptide
Peptide YY
Peptides
Enteroendocrine Cells
High Fat Diet
Therapeutics
Corticosterone
Glucagon
Energy Metabolism
Meals
Insulin Resistance
gastric inhibitory polypeptide receptor
peptide YY (3-36)
Fasting
Homeostasis
Obesity
Eating
Body Weight

Cite this

@article{db7d3733679a4dfa990d03b88d52313c,
title = "Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice",
abstract = "Glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY) are secreted from the intestinal K- and L-cells, respectively, following a meal. Both peptides are believed to play a key role in glucose homeostasis and energy expenditure. This study investigated the effects of daily administration of the stable and specific GIP-R antagonist, (Pro)GIP (25 nmol/ kg) and the endogenous truncated form of PYY, PYY(3-36) (50 nmol/kg), in mice fed with a high fat diet. Daily i.p. injection of (Pro(3))GIP, PYY(3-36) or combined peptide administration over 24 days significantly (P <0.05-0.01) decreased body weight compared with saline-treated controls without change in food intake. Plasma glucose levels and glucose tolerance were significantly (P <0.05) lowered by (Pro(3))GIP treatment alone, and in combination with PYY(3-36). These changes were accompanied by a slight improvement of insulin sensitivity in all of the treatment groups. (Pro(3))GIP treatment significantly reduced plasma corticosterone (P <0.05), while combined administration with PYY(3-36) significantly lowered serum glucagon (P <0.05). No appreciable changes were observed in either circulating or glucose-stimulated insulin secretion in all treatment groups. (Pro(3))GIP-treated mice had significantly (P <0.01) lowered fasting glucose levels and an improved (P <0.05) glycemic response to feeding. These comparative data indicate that chemical ablation of GIP receptor action using (Pro(3))GIP provides an especially effective means of countering obesity and related abnormalities induced by consumption of high fat energy rich diet. (C) 2007 Elsevier Inc. All rights reserved.",
author = "Nigel Irwin and Kerry Hunter and Peter Flatt",
year = "2007",
month = "11",
doi = "10.1016/j.peptides.2007.08.008",
language = "English",
volume = "28",
pages = "2192--2198",
number = "11",

}

Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice. / Irwin, Nigel; Hunter, Kerry; Flatt, Peter.

Vol. 28, No. 11, 11.2007, p. 2192-2198.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice

AU - Irwin, Nigel

AU - Hunter, Kerry

AU - Flatt, Peter

PY - 2007/11

Y1 - 2007/11

N2 - Glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY) are secreted from the intestinal K- and L-cells, respectively, following a meal. Both peptides are believed to play a key role in glucose homeostasis and energy expenditure. This study investigated the effects of daily administration of the stable and specific GIP-R antagonist, (Pro)GIP (25 nmol/ kg) and the endogenous truncated form of PYY, PYY(3-36) (50 nmol/kg), in mice fed with a high fat diet. Daily i.p. injection of (Pro(3))GIP, PYY(3-36) or combined peptide administration over 24 days significantly (P <0.05-0.01) decreased body weight compared with saline-treated controls without change in food intake. Plasma glucose levels and glucose tolerance were significantly (P <0.05) lowered by (Pro(3))GIP treatment alone, and in combination with PYY(3-36). These changes were accompanied by a slight improvement of insulin sensitivity in all of the treatment groups. (Pro(3))GIP treatment significantly reduced plasma corticosterone (P <0.05), while combined administration with PYY(3-36) significantly lowered serum glucagon (P <0.05). No appreciable changes were observed in either circulating or glucose-stimulated insulin secretion in all treatment groups. (Pro(3))GIP-treated mice had significantly (P <0.01) lowered fasting glucose levels and an improved (P <0.05) glycemic response to feeding. These comparative data indicate that chemical ablation of GIP receptor action using (Pro(3))GIP provides an especially effective means of countering obesity and related abnormalities induced by consumption of high fat energy rich diet. (C) 2007 Elsevier Inc. All rights reserved.

AB - Glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY) are secreted from the intestinal K- and L-cells, respectively, following a meal. Both peptides are believed to play a key role in glucose homeostasis and energy expenditure. This study investigated the effects of daily administration of the stable and specific GIP-R antagonist, (Pro)GIP (25 nmol/ kg) and the endogenous truncated form of PYY, PYY(3-36) (50 nmol/kg), in mice fed with a high fat diet. Daily i.p. injection of (Pro(3))GIP, PYY(3-36) or combined peptide administration over 24 days significantly (P <0.05-0.01) decreased body weight compared with saline-treated controls without change in food intake. Plasma glucose levels and glucose tolerance were significantly (P <0.05) lowered by (Pro(3))GIP treatment alone, and in combination with PYY(3-36). These changes were accompanied by a slight improvement of insulin sensitivity in all of the treatment groups. (Pro(3))GIP treatment significantly reduced plasma corticosterone (P <0.05), while combined administration with PYY(3-36) significantly lowered serum glucagon (P <0.05). No appreciable changes were observed in either circulating or glucose-stimulated insulin secretion in all treatment groups. (Pro(3))GIP-treated mice had significantly (P <0.01) lowered fasting glucose levels and an improved (P <0.05) glycemic response to feeding. These comparative data indicate that chemical ablation of GIP receptor action using (Pro(3))GIP provides an especially effective means of countering obesity and related abnormalities induced by consumption of high fat energy rich diet. (C) 2007 Elsevier Inc. All rights reserved.

U2 - 10.1016/j.peptides.2007.08.008

DO - 10.1016/j.peptides.2007.08.008

M3 - Article

VL - 28

SP - 2192

EP - 2198

IS - 11

ER -